Taking the global phosphoproteomics approach and by comparing the corresponding SILAC (Stable Isotope Labeling by Amino acids in Cell) ratios of EGF (epidermal growth factor) stimulation and erlotinib (EGFR inhibitor) treatment in lung adenocarcinoma cells, a prior study identified two serine sites S648 and S708 in the middle domain of MAP4K4 as EGFR (epidermal growth factor receptor) signaling-dependent phosphorylation sites [22]. The gene discussed is MAP4K4; the disease is lung adenocarcinoma.